Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck collaboration — Daiichi Sankyo (3 DXd ADC Oncology Programs) ($M) ($M)
Form 10-Q / 10-K Note 3/4 Collaborative Arrangements
Latest, FY2025
66
Period ended Dec 31, 2025
Change on a year earlier
–
0 in FY2024
History
3 years
Since FY2023
Sources
1
Form 10-K (filed 2026-02-24)
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Collaboration — Daiichi Sankyo (3 DXd ADC Oncology Programs) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 66 | – | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 0 | – | Form 10-K (filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 0 | – | Form 10-K (filed 2026-02-24) ↗ |
Breakdown
What makes up collaboration — daiichi sankyo (3 dxd adc oncology programs) ($m)
- Daiichi Sankyo (3 DXd ADC Oncology Programs) — Current receivables from partner ($M)15 · FY2025
- Daiichi Sankyo (3 DXd ADC Oncology Programs) — Current payables / liabilities to partner ($M)113 · FY2025
- Daiichi Sankyo (3 DXd ADC Oncology Programs) — Cost of sales profit-sharing & manufacturing ($M)66 · FY2025
- Daiichi Sankyo (3 DXd ADC Oncology Programs) — Net R&D cost-sharing expense ($M)524 · FY2025
- Daiichi Sankyo (3 DXd ADC Oncology Programs) — Commercialization / SG&A expense sharing ($M)28 · FY2025
Cite this data
StockData. (2026). Merck Collaboration — Daiichi Sankyo (3 DXd ADC Oncology Programs) ($M) ($M), annual FY2023–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/collab_daiichisankyo
See every metric in the Merck KPI table. Data updated Oct 26, 2026.